Profound Medical Corp. (PROF)
Nasdaq · Healthcare · Medical Devices
$6.03+3.25%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $220M
- 52-week range
- $4.80 – $8.95
- 52-week change
- +1.04%
- EPS (trailing)
- −$0.99
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $16.1M (+50.73%)
- Net income
- −$42.6M
- Operating margin
- −256.3%
- Diluted EPS
- $1.41
- Free cash flow
- −$38.4M
From the company’s annual report on SEC EDGAR.
About Profound Medical Corp.
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.
Headquarters: Mississauga, Canada · 162 employees · profoundmedical.com